Module 9 Quiz

A  Fungal cells

B  Human cells

C  All cell types

D  Bacterial cells

A  Number of chromosomes

B  Structure of chromosomes

C  Number of genes

D  Presence of double-stranded DNA

A  making a cDNA from an mRNA strand.

B  binding of the primers to the single-stranded DNA.

C  adding nucleotides to primed sites of the DNA strands.

D  unwinding and separating the double-stranded DNA.

A  Addition of a deoxyribonucleotide

B  Addition of a ribonucleotide

C  Addition of a dideoxynucleotide

D  Deletion of a deoxyribonucleotide

A  Oligoligated control

B  Blank control

C  dTTP control

D  Positive control

A  Restriction enzyme

B  Polymerase

C  Transcriptase

D  Lysozyme

A  sequence of nucleotides that codes for a protein.

B  sequence of three nucleotides.

C  polymeric molecule composed of nucleic acids.

D  phosphate group, a ribose sugar, and nitrogen.

A  Phosphate group

B  Methyl group

C  Hydroxyl group

D  Hydrogen

A  histones.

B  nucleotides.

C  hormones.

D  lysosomes.

A  30%

B  60%

C  40%

D  20%

A  toxin effect.

B  pattern constellation.

C  metabolic pattern.

D  toxidrome.

A  immunoassay.

B  flame ionization gas chromatography (GC).

C  spectrophotometry.

D  HPLC.

A  The hepatic necrosis is caused by depletion of a substance in the liver and eventual accumulation of the oxidized metabolite.

B  The myocardial infarction is caused by the effect on respiratory centers in the brain and eventual lack of stimulation of the heart.

C  The coma produced is caused by an immediate decrease in sensitivity to CO2 concentration through depression of respiratory centers in the brain.

D  The metabolic acidosis produced is caused by increased formation of formic acid by the liver during metabolism.

A  [Cl−] + [Na+ +  [HCO3-]

B  [Na+] + [Cl− +  [HCO3-]

C  [Na+] − [Cl− +  [HCO3-]

D  [HCO3-]  − [Na+ + Cl−].

A  a more sensitive and specific immunoassay procedure.

B  GC-MS.

C  a spot test.

D  electrophoresis.

A  There is no specific time that is the best for blood collection.

B  At 8 AM, when liver metabolism is highest.

C  Immediately after a dose of the drug is given.

D  Immediately before a dose of the drug is given.

A  To monitor significant drug-drug interactions

B  To monitor drugs with a broad therapeutic range

C  To check patient compliance

D  To determine drug concentrations in a pathophysiological state

A  Using a single drug as opposed to multiple drugs for treatment

B  Using a different route of administration than is typically used for that drug

C  Increased drug metabolism caused by central nervous system disease

D  Decreased renal elimination leading to increased free drug concentration

A  α1-Glycoprotein

B  Albumin, Lipoprotein, and α1-Glycoprotein

C  Lipoprotein

D  Albumin

A  dosing curve.

B  volume of distribution.

C  subtherapeutic range.

D  half-life.